Classification of patients with metastatic colorectal cancer into consensus molecular subtypes into real-world: A pilot study

Figure 1 Proportion of patients in each consensus molecular subtype after analysis by the Tumour Board among the 26 patients included on the final analysis. A specific consensus molecular subtype (CMS) was successfully identified in 24 out of the 26 patients. CMS1 n = 6. CMS2 n = 5. CMS3 n = 8. CMS4 n = 5. Not classifiable n = 2. Each patient underwent an individual assessment by the Tumour Board, and a consensus was reached to determine their molecular subtype. Classification was based on clinical and histological characteristics, as well as the results of RT-qPCR (β-catenin, c-MYC and TGF- β) and NGS (TumorSec panel). CMS: Consensus molecular subtypes.

Figure 2 Classification of patients into consensus molecular subtype categories. A: Kaplan-Meier Curve with overall survival (OS) of the n = 26 patients included on the final analysis. mOS = 28 mo; B: Kaplan-Meier curve which shows OS of patients based on their molecular subtype classification. The median overall survival times were 11, 20, 30, and 45 mo for CMS1, CMS2, CMS3, and CMS4, respectively. There were no statistically significant differences observed among the studied groups (P = 0.0968).